Stock listing

OTC:ELTP Elite Pharmaceuticals, Inc. Stock

Follow Elite Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · OTC:ELTP

$0.322 USD -0.036 (-10.1%)

Close on Nov 20, 2026

Past year -40.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.315 – $0.336 USDNov 20, 2026
Volume
155,111 sharesNov 20, 2026
Market cap
$347.2M USDAt the close on Nov 20, 2026 · price × 1.08B shares outstanding
52-week range
$0.210 – $0.550 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$210,655 USDMedian day 595,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Elite Pharmaceuticals, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ELTP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.322-0.036-10.1%$0.316$0.336$0.315155,111
$0.359-0.010-2.8%$0.375$0.375$0.340343,562
$0.369-0.001-0.3%$0.373$0.392$0.358568,878
$0.370+0.050+15.6%$0.335$0.375$0.3251,085,586
$0.320+0.070+28.0%$0.250$0.350$0.2504,629,500
$0.250+0.010+4.2%$0.220$0.250$0.220225,800
$0.2400.0000.0%$0.210$0.250$0.210866,100
$0.2400.0000.0%$0.240$0.250$0.230383,900
$0.2400.0000.0%$0.240$0.250$0.240241,200
$0.2400.0000.0%$0.240$0.240$0.240488,200
$0.2400.0000.0%$0.240$0.250$0.220700,300
$0.2400.0000.0%$0.240$0.250$0.220396,100
$0.240+0.020+9.1%$0.230$0.250$0.220809,700
$0.220-0.010-4.3%$0.230$0.230$0.220326,100
$0.2300.0000.0%$0.230$0.230$0.220796,100
$0.230-0.010-4.2%$0.250$0.250$0.2301,528,100
$0.2400.0000.0%$0.240$0.250$0.240199,700
$0.240-0.010-4.0%$0.250$0.250$0.240206,000
$0.2500.0000.0%$0.250$0.260$0.2301,229,800
$0.2500.0000.0%$0.250$0.260$0.230297,000
$0.2500.0000.0%$0.250$0.250$0.240258,900
$0.2500.0000.0%$0.240$0.250$0.240223,400
$0.2500.0000.0%$0.250$0.260$0.240742,300
$0.2500.0000.0%$0.250$0.260$0.240488,700
$0.2500.0000.0%$0.260$0.260$0.240509,600
$0.2500.0000.0%$0.250$0.260$0.220710,400
$0.250-0.010-3.8%$0.250$0.260$0.240481,300
$0.2600.0000.0%$0.250$0.260$0.250353,400
$0.2600.0000.0%$0.260$0.260$0.250384,900
$0.260-0.010-3.7%$0.260$0.270$0.250638,500
$0.270+0.020+8.0%$0.250$0.270$0.250829,100
$0.2500.0000.0%$0.250$0.260$0.240580,700
$0.250+0.030+13.6%$0.230$0.250$0.2201,660,000
$0.220-0.010-4.3%$0.220$0.230$0.2101,657,800
$0.2300.0000.0%$0.230$0.240$0.2201,868,100
$0.230-0.010-4.2%$0.240$0.240$0.2301,153,800
$0.2400.0000.0%$0.240$0.250$0.240659,000
$0.240-0.010-4.0%$0.250$0.250$0.2301,467,300
$0.250-0.010-3.8%$0.260$0.260$0.240641,200
$0.260+0.010+4.0%$0.250$0.260$0.250509,500
$0.2500.0000.0%$0.240$0.250$0.240290,700
$0.2500.0000.0%$0.250$0.250$0.240278,000
$0.250+0.010+4.2%$0.240$0.250$0.240408,700
$0.240-0.010-4.0%$0.250$0.250$0.240327,100
$0.2500.0000.0%$0.250$0.250$0.240462,200
$0.250+0.010+4.2%$0.250$0.250$0.240595,000
$0.240-0.010-4.0%$0.250$0.250$0.240874,900
$0.250-0.010-3.8%$0.260$0.260$0.250534,200
$0.2600.0000.0%$0.250$0.260$0.2501,236,900
$0.260+0.010+4.0%$0.260$0.270$0.250398,000
$0.250-0.010-3.8%$0.260$0.270$0.250854,500
$0.2600.0000.0%$0.260$0.260$0.260373,700
$0.2600.0000.0%$0.260$0.260$0.240685,600
$0.2600.0000.0%$0.260$0.260$0.2502,027,500
$0.260-0.020-7.1%$0.280$0.280$0.2601,521,900
$0.2800.0000.0%$0.280$0.280$0.280342,000
$0.280-0.010-3.4%$0.290$0.290$0.280459,500
$0.2900.0000.0%$0.290$0.290$0.280261,400
$0.2900.0000.0%$0.300$0.300$0.2901,930,000
$0.2900.0000.0%$0.290$0.290$0.2801,481,200
$0.2900.0000.0%$0.290$0.290$0.280954,700
$0.2900.0000.0%$0.290$0.290$0.280998,100
$0.290-0.010-3.3%$0.300$0.300$0.290700,800
$0.3000.0000.0%$0.300$0.310$0.280900,900
$0.3000.0000.0%$0.300$0.310$0.2901,322,300
Ticker
OTC:ELTP
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Elite Pharmaceuticals, Inc. news

Elite Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
3 in the last 12 months · 3 in all · newest Nov 12, 2026 · oldest 2026
Decks
1 deck · latest November 2005

Valuation

P/E 5.8× against a median of 10.8×: the lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$312.3M USD
P/E
5.8×
EV/sales
2.2×
EV/EBITDA
8.3×
Price/book
2.8×
Gross margin
43.7%
Operating margin
25.3%
Net margin
41.6%
Debt to equity
0.0×
Beta vs S&P 500
0.53

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Elite Pharmaceuticals, Inc. · OTC:ELTPUS$347.2MUS$312.3M5.8×2.2×8.3×2.8×41.6%0.0×0.53
Wuhan Hiteck Biological Pharma Co., Ltd. Class A · SZSE:300683US$368.3MUS$313.1Mn/a4.8×n/a1.2×−44.4%0.0×n/a
Blau Farmaceutica SA · BMFBOVESPA:BLAU3US$364.0MUS$358.7M9.2×1.2×5.1×0.9×13.1%0.4×n/a
Boiron SA · EURONEXT:BOIUS$359.2MUS$329.7M10.0×0.6×4.5×0.9×6.5%0.1×n/a
Abbott Laboratories Pakistan Limited · PSX:ABOTUS$358.9MUS$321.3M10.7×1.1×5.5×2.9×11.9%0.0×n/a
Unichem Laboratories Limited · NSE:UNICHEMLABUS$356.3MUS$356.3M10.8×1.4×14.4×1.2×13.2%0.0×n/a
Guizhou Yibai Pharmaceutical Co. Ltd. Class A · SSE:600594US$333.3MUS$285.8Mn/a1.4×n/a1.1×−28.0%0.0×n/a
Guangdong Lifestrong Pharmacy Co., Ltd. Class A · SZSE:301111US$332.8MUS$274.7M335×6.1×n/a3.0×2.2%0.0×n/a
Anhui Fengyuan Pharmaceutical Co., Ltd Class A · SZSE:000153US$330.6MUS$287.6M26.0×0.6×n/a1.0×2.7%0.1×n/a
Tuoxin Pharmaceutical Group Co., Ltd. Class A · SZSE:301089US$328.8MUS$300.1Mn/a4.7×n/a1.5×−18.7%0.0×n/a
Mayne Pharma Group Ltd. · ASX:MYXUS$327.4MUS$301.5M20.2×1.2×15.5×1.3×6.4%0.1×n/a
Median of the othersUS$344.8MUS$307.3M10.8×1.3×5.5×1.2×4.5%0.0×

Team and board

Officers

OfficerRole
Nasrat HakimChairman, President & Chief Executive Officer
Carter WardChief Financial Officer
Dianne WillInvestor Relations
Doug PlasscheExecutive Vice President of Operations
G. Kenneth SmithVice President of Legal
Chris DickHead of Development
Kirko KirkovChief Commercial Officer

Board

DirectorRole
Nasrat HakimChairman, President & Chief Executive Officer
Barry DashDirector
Davis S. CaskeyDirector
Jeffrey WhitnellDirector

Events

QuarterResultsShare move
Q1 2027Aug 14, 2026 · After close0.0%
Q2 2026Nov 13, 2025 · After close+1.5%
Q1 2026Aug 12, 2025 · Before open0.0%
Q4 2025Jun 30, 2025−5.6%
Q3 2025Feb 12, 2025 · After close0.0%
Q2 2025Nov 14, 2024 · After close+7.7%
Q1 2025Aug 14, 2024 · After close−5.0%
Q3 2024Feb 15, 2024 · After close+5.6%
Q2 2024Nov 14, 2023 · After close+16.7%
Q1 2024Aug 14, 2023 · After close+25.0%
All 20 quarters
QuarterResultsShare move
Q4 2023Jun 29, 20230.0%
Q3 2023Feb 14, 20230.0%
Q2 2023Nov 15, 2022−25.0%
Q1 2023Aug 15, 20220.0%
Q4 2022Jun 29, 2022+25.0%
Q3 2022Feb 14, 20220.0%
Quarter to Sep 30, 2021Nov 15, 20210.0%
Quarter to Jun 30, 2021Aug 16, 20210.0%
Quarter to Mar 31, 2021Jun 14, 2021−16.7%
Quarter to Dec 31, 2020Feb 17, 2021−25.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2005)Investor deck33 slidesNovember 2005

Open Decks

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue148.9M84.0M56.6M34.2M32.3M25.4M18.0M7.57M7.46M9.64M
Cost of revenue73.8M44.0M30.3M17.6M17.5M13.5M10.0M4.70M3.51M5.90M
Gross profit75.0M40.1M26.4M16.6M14.8M11.9M7.98M2.87M3.95M3.74M
Research and development5.74M7.96M6.88M6.20M4.05M5.11M5.53M7.60M9.62M8.30M
Operating income49.1M19.6M10.8M3.68M5.07M2.10M-2.29M-9.16M-9.05M-7.36M
Depreciation and amortization1.07M1.23M1.32M1.28M1.21M1.31M1.32M1.26M996.4K714.5K
EBITDA50.2M20.8M12.1M4.95M6.28M3.42M-965.6K-7.90M-8.05M-6.64M
Interest expense111.4K128.2K588.6K1.11M191.8K259.6K355.9K369.2K335.5K238.2K
Income before tax56.8M-52.1K463.1K3.99M6.30M4.14M-2.24M-9.96M-4.72M1.94M
Income tax11.9M4.26M-19.6M424.0K-1.74M-676.0K-1.05M-1.87M
Net income44.9M-4.31M20.1M3.56M8.90M5.09M-2.24M-9.28M-3.67M3.81M
Earnings per share, basic0.040.000.020.000.010.010.00-0.010.000.03
Earnings per share, diluted0.030.000.020.000.010.000.00-0.01-0.01-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents29.8M11.3M7.11M7.83M8.54M3.19M1.13M2.28M7.18M10.6M
Receivables59.7M29.2M19.5M3.09M3.06M3.50M4.11M1.32M675.9K934.1K
Inventory21.3M16.2M12.9M9.55M6.74M5.01M4.14M4.52M4.90M6.42M
Current assets112.1M57.7M40.0M21.5M18.9M12.2M10.3M8.86M13.7M18.4M
Property, plant and equipment10.2M10.3M10.2M10.4M5.95M6.65M7.23M8.44M8.99M9.04M
Total assets138.3M96.4M83.7M40.9M35.1M26.2M25.0M24.4M30.9M34.3M
Accounts payable6.05M2.96M2.71M2.45M1.43M929.7K1.58M1.38M1.66M1.05M
Current liabilities17.4M11.8M13.0M7.83M6.69M5.81M8.64M6.91M5.11M3.34M
Total debt1.25M1.47M1.57M
Total liabilities39.4M42.9M26.1M11.9M9.93M10.0M14.3M13.0M12.4M8.65M
Shareholders' equity98.9M53.5M57.6M29.0M25.2M16.2M10.7M-2.51M4.57M25.7M
Shares outstanding1.08B1.07B1.07B1.01B1.01B1.01B840.4M824.8M802.5M927.9M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations23.7M7.46M-3.24M3.34M6.51M3.19M-1.79M-6.79M-4.81M-7.88M
Capital spending-925.6K-1.63M-809.7K-5.74M-498.6K
Free cash flow22.8M5.83M-4.04M-2.40M6.01M
Cash from investing-925.6K-2.40M-809.7K-5.74M-498.6K-262.8K-35.0K330.9K-274.8K-1.10M
Cash from financing-4.32M-825.7K3.34M1.70M-667.1K-869.8K689.5K1.57M1.67M8.07M
Change in cash18.5M4.23M-705.6K-695.7K5.34M2.06M-1.14M-4.90M-3.41M-917.5K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026Current reportSEC
3 · Initial statement of ownershipNov 9, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 6, 2026Insider tradeSEC
8-K · Current reportNov 3, 2026Management or board changeSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K/A · Current report, amendedAug 10, 2026Current reportSEC
8-K · Current reportAug 10, 2026Current reportSEC
8-K · Current reportAug 4, 2026Current reportSEC
8-K · Current reportJun 29, 2026ResultsSEC
10-K · Annual reportJun 29, 2026Annual reportSEC
8-K · Current reportJun 23, 2026Current reportSEC
8-K · Current reportJun 15, 2026Current reportSEC
8-K · Current reportJun 1, 2026Current reportSEC
UPLOAD · Letter from the SECApr 14, 2026Other filingsSEC
8-K · Current reportApr 2, 2026Current reportSEC
CORRESP · Letter to the SECMar 18, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 4, 2026Other filingsSEC
8-K · Current reportFeb 17, 2026ResultsSEC
10-Q · Quarterly reportFeb 17, 2026Quarterly reportSEC
8-K · Current reportFeb 11, 2026Current reportSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
8-K · Current reportNov 14, 2025ResultsSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K/A · Current report, amendedNov 12, 2025Current reportSEC
8-K · Current reportNov 12, 2025Current reportSEC
8-K · Current reportNov 10, 2025Current reportSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
8-K · Current reportAug 14, 2025ResultsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025Current reportSEC
4 · Change in ownershipJul 25, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
144 · Notice of proposed saleJul 8, 2025Other filingsSEC
8-K · Current reportJun 30, 2025ResultsSEC
10-K · Annual reportJun 30, 2025Annual reportSEC
8-K · Current reportJun 23, 2025Current reportSEC
8-K · Current reportJun 16, 2025Current reportSEC
8-K · Current reportApr 30, 2025Current reportSEC
8-K · Current reportMar 3, 2025Current reportSEC
8-K · Current reportFeb 13, 2025ResultsSEC
10-Q · Quarterly reportFeb 13, 2025Quarterly reportSEC
8-K · Current reportDec 26, 2024Current reportSEC
8-K · Current reportDec 2, 2024Current reportSEC
8-K · Current reportNov 18, 2024Current reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
4 · Change in ownershipOct 28, 2024Insider tradeSEC
144 · Notice of proposed saleOct 23, 2024Other filingsSEC
8-K · Current reportOct 10, 2024Current reportSEC
8-K · Current reportOct 7, 2024Current reportSEC
8-K · Current reportAug 27, 2024Current reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
S-8 · Registration statement for employee plansJul 1, 2024Offer documentSEC
8-K · Current reportJul 1, 2024ResultsSEC
10-K · Annual reportJul 1, 2024Annual reportSEC
8-K · Current reportJun 21, 2024Material contractSEC
8-K · Current reportJun 5, 2024Current reportSEC
8-K · Current reportMay 20, 2024Current reportSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 2, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
UPLOAD · Letter from the SECFeb 28, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 20, 2024Other filingsSEC
8-K · Current reportFeb 14, 2024ResultsSEC
10-Q · Quarterly reportFeb 14, 2024Quarterly reportSEC
UPLOAD · Letter from the SECJan 22, 2024Other filingsSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
8-K · Current reportDec 26, 2023Current reportSEC
8-K · Current reportDec 12, 2023Current reportSEC
4 · Change in ownershipNov 27, 2023Insider tradeSEC
4 · Change in ownershipNov 27, 2023Insider tradeSEC
4 · Change in ownershipNov 27, 2023Insider tradeSEC
8-K · Current reportNov 14, 2023ResultsSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportSep 25, 2023Current reportSEC
8-K · Current reportSep 7, 2023Material contractSEC
8-K · Current reportAug 14, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
10-K/A · Annual report, amendedJul 31, 2023Annual reportSEC
8-K · Current reportJul 17, 2023Current reportSEC
8-K · Current reportJun 29, 2023ResultsSEC
10-K · Annual reportJun 29, 2023Annual reportSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 8, 2023Insider tradeSEC
8-K · Current reportMay 3, 2023Material contractSEC
8-K · Current reportApr 20, 2023Current reportSEC
8-K · Current reportFeb 28, 2023Management or board changeSEC
8-K · Current reportFeb 14, 2023ResultsSEC
10-Q · Quarterly reportFeb 14, 2023Quarterly reportSEC
8-K · Current reportDec 22, 2022Current reportSEC
8-K · Current reportNov 28, 2022Material contractSEC
8-K · Current reportNov 15, 2022ResultsSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
4 · Change in ownershipNov 14, 2022Insider tradeSEC
8-K · Current reportNov 10, 2022Current reportSEC
8-K · Current reportNov 2, 2022Current reportSEC
3 · Initial statement of ownershipSep 13, 2022Insider tradeSEC
8-K · Current reportSep 7, 2022Material contractSEC
4 · Change in ownershipAug 29, 2022Insider tradeSEC
4 · Change in ownershipAug 29, 2022Insider tradeSEC
4 · Change in ownershipAug 29, 2022Insider tradeSEC
8-K · Current reportAug 26, 2022Current reportSEC
8-K · Current reportAug 15, 2022ResultsSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
4 · Change in ownershipJul 7, 2022Insider tradeSEC
8-K · Current reportJun 29, 2022ResultsSEC
10-K · Annual reportJun 29, 2022Annual reportSEC
8-K · Current reportJun 29, 2022Current reportSEC
3 · Initial statement of ownershipJun 3, 2022Insider tradeSEC
8-K · Current reportMay 11, 2022Material contractSEC
8-K · Current reportApr 18, 2022Management or board changeSEC
8-K · Current reportApr 4, 2022Current reportSEC
8-K · Current reportFeb 14, 2022ResultsSEC
10-Q · Quarterly reportFeb 14, 2022Quarterly reportSEC
8-K · Current reportDec 9, 2021Material contractSEC
8-K · Current reportDec 2, 2021Material contractSEC
8-K · Current reportDec 2, 2021Material contractSEC
8-K · Current reportNov 15, 2021ResultsSEC
10-Q · Quarterly reportNov 15, 2021Quarterly reportSEC
8-K · Current reportAug 16, 2021ResultsSEC
10-Q · Quarterly reportAug 16, 2021Quarterly reportSEC
4 · Change in ownershipJul 7, 2021Insider tradeSEC
4 · Change in ownershipJul 1, 2021Insider tradeSEC
4 · Change in ownershipJul 1, 2021Insider tradeSEC
4 · Change in ownershipJul 1, 2021Insider tradeSEC
10-K/A · Annual report, amendedJun 22, 2021Annual reportSEC
8-K · Current reportJun 14, 2021ResultsSEC
10-K · Annual reportJun 14, 2021Annual reportSEC
3 · Initial statement of ownershipMay 19, 2021Insider tradeSEC
8-K · Current reportMay 5, 2021Current reportSEC
8-K · Current reportApr 29, 2021Material contractSEC
8-K · Current reportApr 12, 2021Management or board changeSEC
UPLOAD · Letter from the SECMar 12, 2021Other filingsSEC
CORRESP · Letter to the SECFeb 22, 2021Other filingsSEC
8-K · Current reportFeb 16, 2021ResultsSEC
10-Q · Quarterly reportFeb 16, 2021Quarterly reportSEC
UPLOAD · Letter from the SECFeb 9, 2021Other filingsSEC
8-K · Current reportNov 16, 2020ResultsSEC
10-Q · Quarterly reportNov 16, 2020Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedSep 1, 2020Big-stake noticeSEC
8-K · Current reportAug 27, 2020FinancingSEC
4 · Change in ownershipAug 26, 2020Insider tradeSEC
4 · Change in ownershipAug 24, 2020Insider tradeSEC
4 · Change in ownershipAug 24, 2020Insider tradeSEC
4 · Change in ownershipAug 24, 2020Insider tradeSEC
4 · Change in ownershipAug 24, 2020Insider tradeSEC
8-K · Current reportAug 17, 2020ResultsSEC
10-Q · Quarterly reportAug 14, 2020Quarterly reportSEC
8-K/A · Current report, amendedJul 31, 2020Current reportSEC
EFFECT · Notice that a registration is effectiveJul 28, 2020Other filingsSEC
424B3 · ProspectusJul 27, 2020Offer documentSEC
CORRESP · Letter to the SECJul 23, 2020Other filingsSEC
UPLOAD · Letter from the SECJul 22, 2020Other filingsSEC
S-3 · Registration statementJul 15, 2020Offer documentSEC
DJul 13, 2020Other filingsSEC
8-K · Current reportJul 9, 2020Material contractSEC
4 · Change in ownershipJul 6, 2020Insider tradeSEC
8-K · Current reportJun 29, 2020ResultsSEC
10-K · Annual reportJun 29, 2020Annual reportSEC
8-K · Current reportJun 24, 2020Meeting outcomeSEC
DEFA14A · Additional proxy materialMay 11, 2020Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2020Meeting noticeSEC
8-K · Current reportApr 22, 2020Current reportSEC
PRE 14A · Preliminary proxy statementApr 17, 2020Meeting noticeSEC
8-K · Current reportFeb 26, 2020Material contractSEC
8-K · Current reportFeb 10, 2020ResultsSEC
10-Q · Quarterly reportFeb 10, 2020Quarterly reportSEC
8-K · Current reportDec 12, 2019Current reportSEC
8-K · Current reportDec 5, 2019Meeting outcomeSEC
8-K · Current reportNov 19, 2019Material contractSEC
8-K · Current reportNov 12, 2019ResultsSEC
10-Q · Quarterly reportNov 12, 2019Quarterly reportSEC
DEFA14A · Additional proxy materialOct 18, 2019Meeting noticeSEC
DEF 14A · Proxy statementOct 10, 2019Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 27, 2019Meeting noticeSEC
8-K · Current reportSep 12, 2019Current reportSEC
8-K · Current reportAug 9, 2019ResultsSEC
10-Q · Quarterly reportAug 9, 2019Quarterly reportSEC
8-K · Current reportJun 21, 2019ResultsSEC
10-K · Annual reportJun 21, 2019Annual reportSEC
NT 10-K · Late filing noticeJun 14, 2019Explanation requestSEC
8-K · Current reportMar 11, 2019Material contractSEC
8-K · Current reportFeb 11, 2019ResultsSEC
10-Q · Quarterly reportFeb 11, 2019Quarterly reportSEC
8-K · Current reportJan 3, 2019Current reportSEC
8-K · Current reportDec 10, 2018Current reportSEC
8-K · Current reportNov 20, 2018Current reportSEC
8-K · Current reportNov 9, 2018ResultsSEC
10-Q · Quarterly reportNov 9, 2018Quarterly reportSEC
8-K · Current reportNov 5, 2018Current reportSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Elite Pharmaceuticals, Inc.’s releases · as of Nov 12, 2026

Common shares
1,077,569,775
Fully diluted
1,077,569,775

Fully diluted

LineSharesAs of
Common shares1,077,569,775Nov 12, 2026

Share count over time

CountShares
Nov 12, 20261,077,569,775

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Dash Barry H
Director
Buy100,000USD 0.26US$25,980Oct 9, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jerry Treppel
Other companies: Akorn Inc (Director · Jan 13, 2006 – Aug 7, 2009 · Past)
Chairman of Board, Director · Oct 28, 2008 – Nov 13, 2015 · Past
Barry DashDirector · Since at least Aug 28, 2022
Carter WardChief Financial Officer · Since at least Nov 5, 2026
Charan BehlExec V.P. & Chief Sci Officer · Mar 9, 2006 – Nov 13, 2006 · Past
Chris DickHead of Development · Since at least Nov 4, 2026
Davis S. CaskeyDirector · Since at least Feb 26, 2018
Dianne WillInvestor Relations · Since at least Nov 3, 2026
Doug PlasscheExecutive Vice President of Operations · Since at least Nov 4, 2026
G. Kenneth SmithVice President of Legal · Since at least Nov 5, 2026
Jeffrey WhitnellDirector · Since at least Nov 5, 2026
All 15 people
PersonSeat
Kirko KirkovChief Commercial Officer · Since at least Sep 6, 2022
Marc BregmanCFO, Secretary, Treasurer · May 17, 2021 – May 17, 2021 · Past
Mark N PellegrinoCFO, Secretary, Treasurer · May 1, 2023 – May 1, 2023 · Past
Nasrat HakimChairman, President & Chief Executive Officer · Since at least Nov 3, 2026
Robert C J ChenCFO, Secretary, Treasurer · May 16, 2022 – May 16, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Elite Pharmaceuticals, Inc.